Halda adds $126M to test oral drugs for prostate, breast cancer

Kyle LaHucik

Senior Reporter

Connecticut biotech Halda Therapeutics, created by Arvinas founder Craig Crews, has reeled in another $126 million to start clinical testing of its oral molecules for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Halda adds $126M to test oral drugs for prostate, breast cancer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

Hal­da adds $126M to test oral drugs for prostate, breast can­cer

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Halda adds $126M to test oral drugs for prostate, breast cancer